Scientists Develop Proprietary Technology Addressing Issues on the Rise with Unregulated CBD- and Delta-8-THC based Products
GREENVILLE, SC / ACCESSWIRE / April 18, 2024 / Products containing cannabidiol (CBD) and other legal hemp-derived THC alternatives have become increasingly popular and are appearing in stores and online throughout the United States. Given the prohibited status of Delta-9-THC in 22 states, usage of Delta-8-THC in particular, and CBD have become prevalent in the marketplace due to their similar but less psychoactive biological effects. These products are highly unregulated and have led to concerns regarding cannabinoid composition and overall safety. Additionally, usage of these products has made drug testing complicated to interpret because the chemical structures are similar and cannot be differentiated by standard drug testing methods. Luxor Scientific, LLC and Clearwater BioTech, LLC are working together to tackle these concerns with hemp-derived cannabinoid products.
Luxor Scientific, LLC, a full-service medical and research laboratory, has designed the CannabisConfirm™ panel, a first of its kind urine testing method to provide evidence for employers and healthcare providers as to whether an individual has consumed Delta-9-THC, Delta-8-THC, CBD and/or other cannabinoids. Compared to traditional laboratory practices, CannabisConfirm™ gives practitioners and employers the ability to identify legal versus illicit cannabis use. It is critical for healthcare providers and employers alike to be able to ensure that toxicology tests accurately represent a patient or prospective employee’s use of cannabis products.
